Other studies investigating the clinical evidence of dual inhibition of EGFR and MET with small molecule inhibitors or monoclonal antibodies, such as capmatinib plus geftinib, telisotuzumab plus erlotinib, savolitinib plus geftinib, onartuzumab plus erlotinib, capmatinib plus erlotinib, and emibetuzumab plus erlotinib within patients with NSCLC with EGFR-mutant and MET alterations, are summarized in Table 1 [71,72,73,94,95,96,97,98,99,100,101]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.